Cartesian Therapeutics, Inc.
RNAC
Peringkat dalam Saham
#18165
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Harga Saham
$6.44
Terakhir disinkronkan: 2026-10-21
Kapitalisasi Pasar
$194.84M
Perubahan (1 hari)
0.70%
Perubahan (1 tahun)
865.08%
Negara
US
Perdagangan Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Riwayat harga saham Cartesian Therapeutics, Inc. (RNAC)
Harga penutupan tertinggi: $0.79 pada 2023-12-01
Harga penutupan terendah: $14.00 pada 2016-06-01
Harga penutupan terendah: $14.00 pada 2016-06-01
Riwayat harga saham Cartesian Therapeutics, Inc. dari 2016 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.79 | -3.81% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
